{Reference Type}: Journal Article
{Title}: Honeycomb Epithelial Edema Associated With Rho Kinase Inhibition: A Case Series and Review of the Literature.
{Author}: Lyons LJ;Wu KY;Baratz KH;Sit AJ;
{Journal}: Cornea
{Volume}: 41
{Issue}: 2
{Year}: Feb 2022 1
{Factor}: 3.152
{DOI}: 10.1097/ICO.0000000000002694
{Abstract}: <B>UNASSIGNED: </B>The Rho kinase inhibitor netarsudil is a recently approved therapeutic option for the management of increased intraocular pressure in the United States. Although phase 3 clinical trials noted corneal changes related to the medication-namely, nonvisually-significant corneal verticillata-descriptions of a unique form of cystic epithelial edema began to surface as netarsudil (and its sister drug ripasudil, approved in Japan) gained widespread use. This series adds 3 new cases and reviews the current literature on this unique side effect.